Lumay Pharmaceutical(300006) announced on March 12 that the company recently signed an agreement with Xi'an Wojie Private Equity Fund Management Co., Ltd. and Sansure Biotech.Several institutions, including a technology company, signed a partnership agreement to jointly establish Guangzhou Shengquan Baijie Venture Capital Fund Partnership (Limited Partnership). The fund aims to raise a total of RMB 150 million, of which the company, as a limited partner, will contribute RMB 5 million from its own funds, representing a 3.33% stake.

The investment fund primarily invests in innovative biopharmaceuticals and medical devices .In vitro diagnosticsIn the life and health sectors, investments in these industries shall not be less than 60% of the fund's total paid-in capital. The fund focuses on investing in Guangzhou's strategic emerging industries and future industries, and has established a fund for seed companies in Guangzhou.Investment ratio requirements for early-stage and angel-stage projects.

According to the announcement, the company's investment in this fund will leverage the project resources and investment management capabilities of professional investment institutions to invest in qualified early-stage and growth-stage innovative biopharmaceutical companies. This will accelerate the company's strategic layout in high-barrier, high-growth segments of the pharmaceutical and healthcare industry chain, increasing investment opportunities in the biopharmaceutical field, enriching the company's product line, enhancing profitability, and improving core competitiveness. The company's participation in the investment will be conducted while ensuring sufficient funds for its daily operations and will not have a significant impact on the company's financial condition and operating results.

https://finance.eastmoney.com/a/202603123669700056.html